Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough
Publication date: Available online 14 March 2019Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): David Muccino, Stuart GreenAbstractChronic cough, or cough lasting>8 weeks, is often associated with underlying medical conditions (ie, asthma, gastroesophageal reflux disease, nonasthmatic eosinophilic bronchitis, and upper-airway cough syndrome). In some patients with chronic cough, treatment of these underlying conditions does not resolve the cough (refractory chronic cough [RCC]), or none of these conditions are present (unexplained chronic cough [UCC]). Despite appropriate medical evaluation, patients with RCC or UCC frequently experience cough persisting for many years, as there are currently no targeted pharmacological approaches approved for the treatment of these conditions. However, the adenosine triphosphate (ATP)-gated P2X3 receptor, a key modulator of the activation of sensory neurons central to the cough reflex, has recently garnered attention as a potential therapeutic target for the treatment of chronic cough. Gefapixant, a first-in-class, non-narcotic, selective antagonist of the P2X3 receptor, recently demonstrated efficacy and was generally well-tolerated in phase 2 clinical trials in patients with RCC, validating the utility of targeting this receptor in patients with chronic cough. On the basis of these data, 2 global phase 3 trials, with combined anticipated enrolment exceeding 2000 patients and with treatment durations of up to 1 year, have been...
Conclusions: Negative ICS beliefs are associated with higher number of oral steroid courses. The association between CAM endorsement and asthma control is varied, but mostly in favor of improved control. Financial difficulties may make CAM use more likely. PMID: 32646322 [PubMed - as supplied by publisher]
CONCLUSION: OCT-A is an important tool for the diagnosis of both naïve and fibrotic CNV in BMD patients; it is a non-invasive method for the qualitative and quantitative analysis of neovascular lesions during follow-up. Our results have shown a cyclic remodeling of treated CNV in BMD patients using both PDT and IV. PMID: 32643503 [PubMed - as supplied by publisher]
CORONAVIRUS symptoms include a high fever, a new cough, and loss of smell and taste. But you could also be at risk of COVID-19 infection if you develop a change to your usual toilet habit. Should you consider self-isolating with coronavirus signs?
Publication date: Available online 9 July 2020Source: The Lancet Respiratory MedicineAuthor(s): Richard N van Zyl-Smit, Matthias Krüll, Christian Gessner, Yasuhiro Gon, Oliver Noga, Alexia Richard, Amy de los Reyes, Xu Shu, Abhijit Pethe, Ana-Maria Tanase, Peter D'Andrea, PALLADIUM trial investigators
Publication date: Available online 9 July 2020Source: The Lancet Respiratory MedicineAuthor(s): Guy Brusselle
Publication date: Available online 9 July 2020Source: The Lancet Respiratory MedicineAuthor(s): Huib A M Kerstjens, Jorge Maspero, Kenneth R Chapman, Richard N van Zyl-Smit, Motoi Hosoe, Ana-Maria Tanase, Catherine Lavecchia, Abhijit Pethe, Xu Shu, Peter D'Andrea, IRIDIUM trial investigators
Publication date: Available online 9 July 2020Source: The Lancet Respiratory MedicineAuthor(s): J Christian Virchow
In this study, we particularly focused on microRNA cargo of nanovesicles in bronchoalveolar lavage of severe asthmatic patients when compared to healthy controls. We extracted nanovesicle RNA using a serial filtration method. RNA content was analyzed with small RNA sequencing and mapped to pathways affected using WebGestalt 2017 Software. We report that severe asthma patients have deficient loading of microRNAs into their airway luminal nanovesicles and an altered profile of small RNA nanovesicle content (i.e., ribosomal RNA and broken transcripts, etc.).
Conclusions: Our pooled data indicated that IL-13 + 1923 C > T, -1112 C > T and +2044 A > G polymorphisms were correlated with risk of pediatric asthma. PMID: 32643534 [PubMed - as supplied by publisher]
Publication date: Available online 6 June 2019Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): Li Long, Kefang LaiAbstractChronic cough is one of the most common complains for patients seeking medical attention in both general practice and respiratory specialist clinics. Cough variant asthma, eosinophilic bronchitis, upper airway cough syndrome, as well as gastro-esophageal reflux disease are common conditions associated with chronic cough, and cough variant asthma, eosinophilic bronchitis account for a higher proportion of patients with chronic cough in China than in Western countries. An older female predominan...